Cowen analyst Dan Brennan lowered the firm’s price target on Illumina to $296 from $350 and keeps an Outperform rating on the shares. The analyst said although guidance disappointed again, it feels like the shares are de-risked given the solid X Ramp.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ILMN:
- Illumina Lower after Negative FY23 Outlook
- Illumina guided 2023 significantly below expectations, says Citi
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- Illumina initiated with Sector Perform on Grail uncertainty Scotiabank
- Illumina initiated with a Sector Perform at Scotiabank